Oct. 23 (Bloomberg) -- ImClone Systems Inc. and Merck KGaA’s Erbitux, which doesn’t work for advanced colorectal cancer patients with a certain gene mutation, is also futile in people with a second, unrelated aberration, a study found.
Oct. 23 (Bloomberg) -- ImClone Systems Inc. and Merck KGaA’s Erbitux, which doesn’t work for advanced colorectal cancer patients with a certain gene mutation, is also futile in people with a second, unrelated aberration, a study found.
